Supplemental Data

Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) is upregulated in breast epithelial-mesenchymal transition and responds to oxidative stress

Qiong Wang¹, Sigurdur Trausti Karvelsson¹, Aristotelis Kotronoulas¹, Thorarinn Gudjonsson², Skarphedinn Halldorsson^{1,3}, Ottar Rolfsson¹

¹Center for Systems Biology, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Sturlugata 8, 101 Reykjavik, Iceland.

²Stem Cell Research Unit, Biomedical Center, Department of Anatomy, Faculty of Medicine, School of Health Sciences, University of Iceland, Vatnsmyrarvegi 16, 101 Reykjavík, Iceland.

³Institute for Surgical Research, Vilhelm Magnus Laboratory, Oslo University Hospital, Oslo, Norway.

Corresponding author information

Ottar Rolfsson¹; ottarr@hi.is; Center for Systems Biology, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Sturlugata 8, 101 Reykjavik, Iceland.

List of Materials

Supplemental Figures

Figure S1: LFQ versus SILAC and the proteome of the D492 EMT cell model.

Figure S2: Evaluate the D492 EMT model based on EMT markers from database dbEMT2.

Figure S3: GO annotation of biological processes and KEGG pathway enrichment of differently expressed proteome between two cell lines.

Figure S4: Interaction network of the changed proteome in metabolism.

Figure S5: Glycan metabolic enzymes and the siRNA-mediated knockdown efficiency and O-GlcNAcylation function of GFPT2.

Figure S6: CDH1/CDH2 expression and phenotypes of D492, D492M, and D492HER2 after siRNA-mediated knockdown of *GFPT2*.

Figure S7: Cell images of D492, D492M, and D492HER2 after knockdown of *GFPT2* in proliferation, migration, and invasion.

Figure S8: Metabolomic levels of the glycan precursors and ¹³C tracing from glucose and glutamine.

Figure S9: Glutathione levels with *GFPT2* knockdown and GFPT2 RNA expression after siRNA-mediated knockdown of *NF-\kappa B* (p65).

Supplemental Tables

 Table S1: Primers in this study.

 Table S2: Summary of the LFQ and SILAC proteomic datasets.

Supplemental Data

Supplemental Data 1: MaxQuant output of the LFQ proteomic experiment including protein quantification and peptide information.

Supplemental Data 2: MaxQuant output of the SILAC proteomic experiment including protein quantification and peptide information.

Supplemental Data 3: Signature proteins for D492, D492M, and D492HER2.

Supplemental Data 4: Comparison of the EMT markers between literature and the current study.

Supplemental Data 5: Comparison of the EMT markers between the public database dbEMT2 and the current study.

Supplemental Data 6: MaxQuant output of the iBAQ quantification from the LFQ and SILAC proteomic experiments including protein quantification and peptide information.

Supplemental Data 7: Differently expressed proteins comparing D492, D492M, and D492HER2.

Supplemental Data 8: The enriched KEGG pathways and proteins involved in each pathway comparing D492, D492M, and D492HER2.

Supplemental Data 9: MaxQuant output of the SILAC phosphoproteomic experiment including protein quantification, peptides, and phosphosite information.



Supplemental Figures

Figure S1. LFQ versus SILAC and the proteome of the D492 EMT cell model. (A) The peptides were well fractionated into 10 fractions for the three replicates in the SILAC proteomic experiment. (B) SILAC, which covered 35,000 amino acids length, had a bigger coverage than LFQ in which only 25,000 amino acids were covered for the peptide detection (C). (D-F) The consistency between LFQ and SILAC proteomics datasets regarding ratios of D492M and D492HER2 (D), D492 and D492HER2 (E), and D492 and D492M (F). Pearson comparison coefficients were labeled. Identified and quantified proteins in both the LFQ and SILAC datasets were used for comparison. Proteins needed to be detected in at least two out of three replicates in the LFQ dataset while detected with at least two ratios in three SILAC replicates. Log2 ratios were plotted in the scatter plot with LFQ on the x-axis and SILAC on the y-axis. (G-H) "Signature proteome" among D492, D492M, and D492HER2. Proteomic data based on both LFQ (G) and SILAC (H) have clustered D492M and D492HER2 together. 'Signature proteins' for D492 (C3 and C6), D492M (C2 and C5), and D492HER2 (C1 and C4) were defined as protein groups differentiating different cell types. Protein clusters (C1 and C4) were outlined as "Signature Proteins" in D492HER2. The heatmap of the LFQ proteome was plotted using proteins with significant differences (LFQ, ANOVA, and Permutation-based FDR < 0.05), while the heatmap of the SILAC proteome was plotted using the SILAC data (Coefficient of Variation of SILAC ratios < 0.1) (Supplemental data 3). LFQ: Label-free quantification; SILAC: Stable isotope labeling by amino acids in cell culture.



Figure S2. Evaluate the D492 EMT model based on EMT markers from database dbEMT2. Since the EMT program cannot be defined with limited markers, to comprehensively present the expression levels of EMT markers in different cell lines, we plotted all EMT markers detected in this study based on an open EMT database: dbEMT2 (43). EMT markers detected in the study were clustered into four groups. Pathways were enriched for each cluster based on the Reactome pathway database (Version 72), and top pathways in each group (FDR < 0.01) were listed on the right side. The proteins in each cluster were listed in **Supplemental data 5** along with the relative information.



Figure S3. GO annotation of biological processes and KEGG pathway enrichment of differently expressed proteome between two cell lines. Annotation of the differences in biological processes (BP) between D492HER2 and D492M (A), D492HER2 and D492 (B), and D492M and D492 (C). The whole proteome from the SILAC dataset was used as background. The enriched GO annotation terms with enrichment factor more than 2 for BPs were plotted in descending order (Fisher exact test, Benjamin-Hochberg FDR < 0.02). Supplemental data 7 was used for the GO annotation: Student T-test, Permutation-based FDR < 0.05 for LFQ; One sample T-test, p value of SILAC ratios < 0.05. (D) KEGG pathways which were involved in cell structure, migration, adhesion, nucleotide metabolism, invasion, proteoglycans in cancer, and more. were differently enriched in D492HER2 *versus* D492M. (E) Similar to D492HER2 *versus* D492M, KEGG pathways differently enriched in D492HER2 *versus* D492HER2 *versus* D492M, KEGG pathways differently enriched in D492HER2 *versus* D492HER2 *versus* D492 were cell structure, migration, adhesion, invasion, and proteoglycans in cancer. (F) KEGG pathways differently enriched in D492HER2 were not only involved in adhesion and migration but also in several signaling pathways. Proteins involved in each KEGG pathway were reported in Supplemental data 8.





Figure S4. Interaction network of the changed proteome in metabolism. (A) The Reactome metabolic pathways differently enriched in D492HER2 versus D492M along with the proteins involved were plotted. Proteins marked in orange were upregulated in D492HER2, and proteins marked in red were upregulated in D492M. (B) The Reactome metabolic pathways differently enriched in D492HER2 versus D492 along with the proteins involved were plotted. Proteins marked in orange were upregulated in D492HER2, and proteins marked in blue were upregulated in D492. (C) The Reactome metabolic pathways differently enriched in D492M versus D492 along with the proteins involved were plotted. Proteins marked in red were upregulated in D492M, and proteins marked in blue were upregulated in D492. The gene names with enlarged labels were proteins with at least 2-fold differences between two cell lines. The proteins involved in enriched metabolic pathways (FDR < 0.05) were connected and clustered in STRING (Version 11.0; k-means clustering, minimum required interaction scores: medium confidence 0.400) and visualized in Cytoscape (version 3.5.1/Version 3.6.1). The pathways were enriched with all differentially expressed proteins (Supplemental data 7) between cell lines by Reactome Pathway Enrichment Analysis (Version 65, 67, and 72).



Figure S5. Glycan metabolic enzymes and the siRNA-mediated knockdown efficiency and O-GlcNAcylation function of GFPT2. (A) The RNA level of GALE was higher in D492HER2 than in D492, which was contradictory to the protein level (Fig. 3D). (B-C) The RNA expressions of UGDH and PGM2L1 were consistent with the protein levels in the three D492 cell lines (Fig. 3D). (D) The knockdown efficiency of *GFPT2* with two different siRNAs in the three D492 cell lines showed that both siRNAs had relatively 80 % knockdown efficiency. (E) The knockdown efficiency was similar if not better in MDA-MB-231 compared to the D492 cell lines, with more than 80 %. (F) The protein O-GlcNAcylation was decreased with *GFPT2* knockdown. It was confirmed by the western blot of protein O-GlcNAcylation in the D492 cells treated with two *GFPT2*-targeting siRNAs, using β -actin as the loading control. *: p < 0.05; **: p < 0.01; ***: p < 0.001. GALE: UDP-glucose 4-epimerase; UGDH: UDP-glucose 6dehydrogenase; PGM2L1: Glucose 1,6-bisphosphate synthase; GFPT2: Glutamine-fructose-6-phosphate transaminase 2.



Figure S6. CDH1/CDH2 expression and phenotypes of D492, D492M, and D492HER2 after siRNA-mediated knockdown of GFPT2. (A-C) Knockdown of GFPT2 decreased CDH1 in D492 (A) while increased CDH1 in D492M (B). (D-F) Knockdown of GFPT2 decreased CDH2 in D492M (E) while increased CDH2 in D492HER2 (F). CDH1 was highly expressed in D492 (Fig. 1C), and a decrease in its expression was observed following GFPT2 knockdown. Similarly, CDH2 was highly expressed in D492M (Fig. 1C) but decreased upon knockdown of GFPT2. Both CDH1 and CDH2 were lower in D492HER2 compared to D492 and D492M, respectively (Fig. 1C). GFPT2 knockdown increased the CDH1 expression in D492M and the CDH2 expression in D492HER2. (G) Cell phenotype was not noticeably changed in all D492 cell lines with *GFPT*2 knockdown. *: p < 0.05; **: p < 0.01; ***: p < 0.001. GFPT2: Glutamine-fructose-6-phosphate CDH1: Cadherin-1: CDH2: Cadherin-2; transaminase 2.



Figure S7. Cell images of D492, D492M, and D492HER2 after knockdown of *GFPT2* in proliferation, migration, and invasion. (A) Cell proliferation assay. The representative photos of D492, D492M, and D492HER2 cells with scramble negative control and *GFPT2*-targeting siRNA-mediated treatments in bright-field 24 (48) hours and 90 hours after cell seeding. (B) Invasion Transwell assay. The representative photos of D492HER2 with scramble and two *GFPT2*-targeting siRNA-mediated treatments. The invaded cells that passed through the filters were stained with DAPI. (C) Wound healing assay. The representative photos of D492, D492M, and D492HER2 cells with scramble and *GFPT2*-targeting siRNA-mediated treatments at T0 and 48 hours after wound scratching. DAPI: 4',6-diamidino-2-phenylindole; GFPT2: Glutamine-fructose-6-phosphate transaminase 2.



Figure S8. Metabolomic levels of the glycan precursors and ¹³C tracing from glucose and glutamine. (A-C) No significant differences in UDP-Glc (A), UDP-GlcA (B), and GlcNAc-P (C) were observed among the 492 cell lines. (D-F) The percentage of ¹³C incorporation after 6 hours' cell culture with 1,2-13C Glc (D), 1-13C Gln (E), and 5-13C Gln (F) in all cell lines. (D) UDP-GIcNAc molecules were most with two ¹³C labels, followed by three ¹³C labels in all cell types when culturing with 1,2-13C Glc. The percentage of UDP-GlcNAc with no 13C incorporation from 1,2-13C GIc was higher in D492HER2 than in D492. D492M had the least percentage of UDP-GlcNAc without labels. The percentage of UDP-GlcNAc with three labels from 1,2-13C Glc was the highest in D492M. (E) No 13C incorporation from 1-13C Gln was observed in all cell lines. (F) UDP-GlcNAc was most with no ¹³C label in all cell lines when cultured with 5-13C Gln. The percentage of UDP-GlcNAc with no label from 5-13C Gln was higher in D492M than in D492, while D492M had a significantly lower percentage of UDP-GlcNAc with one label from 5-¹³C Gln as compared to D492. *: p < 0.05; **: p < 0.01; ***: p < 0.01; UDP-GlcA: UDP-Glc: UDP-glucuronate; 0.001. UDP-glucose; GIcNAc-P: Nacetylglucosamine phosphate; Gln: Glutamine.



S-13

Figure S9. Glutathione levels with *GFPT2* knockdown and GFPT2 RNA expression after siRNA-mediated knockdown of *NF-кB* (p65). GSH/GSSG ratios and total glutathione levels after knockdown of *GFPT2* with two siRNAs in D492 (A-B), D492M (C-D), D492HER2 (E-F), and MDA-MB-231 (G-H). Increase of GSH/GSSG ratio and total glutathione level after knockdown of *GFPT2* with the second siRNA in all three D492 cell lines was observed. No significant differences in glutathione level were detected with *GFPT2* knockdown in MDA-MB-231. (I) The two siRNAs targeting *NF-кB* (p65) showed more than 80 % knockdown efficiency. (J) GFPT2 RNA expression was unchanged or increased after knockdown of *NF-kB* (p65, RELA) in D492HER2 with two siRNAs. RELA: the gene encodes NF-*k*B (p65). *: p < 0.05; **: p < 0.01; ***: p < 0.001. GSH: Reduced glutathione; GSSG: Oxidized glutathione; RELA: Proto-Oncogene, NF-*k*B subunit, transcription factor p65; GFPT2: Glutamine-fructose-6-phosphate transaminase 2.

Supplemental Tables

Table S1. Primers in this study.

Genes	Primers	Sequences(5'to3')			
GFPT2	Forward	ATCCTTGCTTCGCCAAATGC			
	Reverse	TTCAGTATCGTCCTTGGAGCAC			
GALE	Forward	TTAGGGCTGGACAGGATGTGTG			
	Reverse	CTGCTGCTTTTCCTGGTCCTTG			
UGDH	Forward	TTTCTGTGCTGTCCAACCCTGA			
	Reverse	CTCTCTGGCCCTCTGGAGTTTC			
PGM2L1	Forward	GGGATCTGAACTCCAACCTGCT			
	Reverse	AAAGACGATCTCGCAGCTCCTT			
CDH1	Forward	ACCACGTACAAGGGTCAGGT			
	Reverse	GGCATCAGCATCAGTCACTT			
CDH2	Forward	CCTGCTTATCCTTGTGCTGA			
	Reverse	CCTGGTCTTCTTCTCCTCCA			
SQOR	Forward	CTTCAGGAAGACAGGGAAGCGA			
	Reverse	TAACAGTGAGGTTCCGCTCCTG			
GSK3B	Forward	GGCAGCAAGGTAACCACAGT			
	Reverse	GATGGCAACCGATTCTCCAG			
RELA (p65)	Forward	CCAGACCAACAACAACCCCT			
	Reverse	TCACTCGGCAGATCTTGAGC			
АСТВ	Forward	CTTCCTGGGTGAGTGGAGACTG			
	Reverse	GAGGGAAATGAGGGCAGGACTT			

Table S2. Summary of the LFQ and SILAC proteomic datasets. Proteins were considered as valid quantification when at least two out of three replicates in one cell line were reported with valid intensities. Protein signature: a list of proteins up- or down-regulated in one cell line compared to the other two cell lines.

			SILAC		
Fractionation	single shot	10 fractions			
Replicates (per cell line)	3	3			
Peptides identified	28,766	67,118 (Replicate 1)	70,314 (Replicate 2)	68,645 (Replicate 3)	
Total protein groups	3,595	7,166 (Replicate 1)	7,390 (Replicate 2)	7,317 (Replicate 3)	
Quantifiable protein detected in at least tw (Proteins were considered as valid and use	2,705	5,120			
D492 vs D492M	Proteins only identified in D492	104	n.a		
(Unique proteins)	Proteins only identified in D492M	142	n.a		
D492HER2 vs. D492	Proteins only identified in D492HER2	129	n.a		
(Unique proteins)	Proteins only detected in D492	123	n.a		
D492HER2 vs. D492M	Proteins only identified in D492HER2	76	n.a		
(Unique proteins)	Proteins only identified in D492M		n.a		
	Proteins only identified in D492	59	n.a		
D492 vs. D492M vs. D492HER2 (Unique proteins)	Proteins only identified in D492M	44	n.a		
	Proteins only identified in D492HER2	31	n.a		
	D492 cell line signature	312 (210 downregulated and 102 upregulated)		ed)	
Protein signatures of all cell lines (Supplementary Data 3)	D492M cell line signature		97 (49 downregulated and 48 upregulated)		
	D492HER2 cell line signature	84 (19 downregulated and 65 upregulated)			